| Source DB | nl |
|---|
| Institution | KU Leuven |
|---|
| Code | edab023c-2fd8-48bf-97bd-38b8011bc1b0 |
|---|
| Unit | 61a9f0d7-1f47-46b1-9a91-25973d85f88e
|
|---|
| Begin | 1/1/2018 |
|---|
| End | 12/31/2021 |
|---|
| title fr |
|
|---|
| title nl | Biologische karakterisatie van auto-antilichamen die geassocieerd zijn met therapierespons in reumatoïde artritis
|
|---|
| title en | Biological characterization of autoantibodies associated with therapy response in rheumatoid arthritis
|
|---|
| Description fr |
|
|---|
| Description nl | Het doel van dit project is om de 3 meest veelbelovende auto-antilichamen en hun doelwitantigenen te karakteriseren en om de biologische betekenis van deze auto-antilichamen in het proces van therapierespons op te helderen
|
|---|
| Description en | Rheumatoid arthritis (RA) is a common inflammatory autoimmune disorder that damages synovial joints and is characterized by the presence of antibodies against self-antigens. Using a highthroughput autoantibody profiling approach, novel predictive antibody biomarkers were identified in a subset of RA patients which fail to respond to a standard therapeutic regimen for RA. The aim of this project is to characterize the 3 most promising autoantibodies and their target antigens, and to elucidate the biological significance of these autoantibodies in the process of therapy response. As the target proteins of these antibodies are still unknown, the identity and tissue expression of the in vivo antigens will first be determined using proteomics and immunohistochemistry. Next, the effector functions of these antibodies will be investigated by measuring the isotype use in a large cohort of well-characterized human serum samples. A detailed characterization of the cellular signaling pathways affected by these antibodies will done in immune cells and human primary cells isolated from joints. Finally, we will use the collagen-induced arthritis mouse model for RA to study the direct effect of passive transfer of our selected antibodies on the efficacy of therapy response. The elucidation of the role of these novel autoantibodies in RA therapy response will provide detailed insight in the mechanisms underlying personalized treatment decisions, leading to a better disease outcome.
|
|---|
| Qualifiers | - Autoantibodies - Rheumatoid arthritis - |
|---|
| Personal | Verschueren Patrick |
|---|
| Collaborations | |
|---|
